Lenient versus Strict Rate Control in Patients with Atrial Fibrillation
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation. METHODS: We randomly assigned 614 patients with permanent atrial fibrillation to undergo a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute). The primary outcome was a composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. The duration of follow-up was at least 2 years, with a maximum of 3 years. RESULTS: The estimated cumulative incidence of the primary outcome at 3 years was 12.9% in the lenient-control group and 14.9% in the strict-control group, with an absolute difference with respect to the lenient-control group of -2.0 percentage points (90% confidence interval, -7.6 to 3.5; P<0.001 for the prespecified noninferiority margin). The frequencies of the components of the primary outcome were similar in the two groups. More patients in the lenient-control group met the heart-rate target or targets (304 [97.7%], vs. 203 [67.0%] in the strict-control group; P<0.001) with fewer total visits (75 [median, 0], vs. 684 [median, 2]; P<0.001). The frequencies of symptoms and adverse events were similar in the two groups. CONCLUSIONS: In patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control and is easier to achieve. (ClinicalTrials.gov number, NCT00392613.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was no difference in a composite of clinical events (14.9% in the strict rate control group, 12.9% in the lenient group), 560 NYHA class, or hospitalizations.560, 561”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [560]
Citations
Cites
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Self-citationVan Gelder, I. C., Hagens, V. E., Bosker, H. A., Kingma, J. H., Kamp, O., Kingma, T., Said, S. A., Darmanata, J. I., Timmermans, A. J. M., Tijssen, J. G. P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021375 · Cited by 2,359
Self-citationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,129
Self-citationAtrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
Anter, E., Jessup, M., & Callans, D. J. (2009) · Circulation · doi:10.1161/circulationaha.108.821306 · Cited by 678
Lechat, P., Hulot, J.-S., Escolano, S., Mallet, A., Leizorovicz, A., Werhlen-Grandjean, M., Pochmalicki, G., & Dargie, H. (2001) · Circulation · doi:10.1161/01.cir.103.10.1428 · Cited by 525
Nerheim, P., Birger-Botkin, S., Piracha, L., & Olshansky, B. (2004) · Circulation · doi:10.1161/01.cir.0000135472.28234.cc · Cited by 378
Van Gelder, I. C., Crijns, H. J. G. M., Blanksma, P. K., Landsman, M. L. J., Posma, J. L., Van Den Berg, M. P., Meijler, F. L., & Lie, K. I. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90352-d · Cited by 269
Self-citationConnolly, S. J., Crijns, H. J. G. M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R. L., & Hohnloser, S. H. (2009) · Circulation · doi:10.1161/circulationaha.109.875252 · Cited by 261
Self-citation
Cited by
Items 201–300 of 999
Varma, N., Cygankiewicz, I., Turakhia, M. P., Heidbüchel, H., Hu, Y., Chen, L. Y., Couderc, J., Cronin, E. M., Estep, J. D., Grieten, L., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12461 · Cited by 39
Genetic suppression of Gαs protein provides rate control in atrial fibrillation
Lugenbiel, P., Thomas, D., Kelemen, K., Trappe, K., Bikou, O., Schweizer, P. A., Voss, F., Becker, R., Katus, H. A., & Bauer, A. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0265-5 · Cited by 38
2025 Clinical practice guidelines for Atrial fibrillation and flutter
Golukhova, E. Z., Sp, G., Михайлов, Е. Н., Revishvili, A. S. H., Arakelyan, M. G., Vasilyeva, E. Y., Davtyan, K. V., Drapkina, O. M., Drozdova, L. Y., Станиславовна, К. Е., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6668 · Cited by 48
Disertori, M., Lombardi, F., Barlera, S., Maggioni, A. P., Favero, C., Franzosi, M. G., Lucci, D., Staszewsky, L. I., Fabbri, G., Quintarelli, S., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.05.008 · Cited by 41
Andrade, J. G., Roy, D., Wyse, D. G., Tardif, J., Talajic, M. R., Leduc, H., Cadrin‐Tourigny, J., Shohoudi, A., Dubuc, M., Rivard, L., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.08.028 · Cited by 40
Pisters, R., Hohnloser, S. H., Connolly, S. J., Torp-Pedersen, C. T., Naditch‐Brûlé, L., Page, R. L., Crijns, H. J. G. M., & for the ATHENA Investigators (2013) · EP Europace · doi:10.1093/europace/eut293 · Cited by 35
Self-citationRogers, P. A., Bernard, M. L., Madias, C. A., Thihalolipavan, S., Estes, N. A. M., & Morin, D. P. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.06.001 · Cited by 39
Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019
Moreira, A. A. C. D. M., Costa, E. F. D. A., Miranda, R. D., Wajngarten, M., Galera, S. C., Filho, A. C. D. A., Toledo, M. A. D. V., Alves, J. D. C., Moriguchi, E. H., Rodrigues, N. L., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190086 · Cited by 44
Estes, N. A. M., Sacco, R. L., Al-Khatib, S. M., Ellinor, P. T., Bezanson, J., Alonso, A., Antzelevitch, C., Brockman, R. G., Chen, P.-S., Chugh, S. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318224b037 · Cited by 35
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 56
Bosch, N. A., Rucci, J. M., Massaro, J. M., Winter, M. R., Quinn, E. K., Chon, K. H., McManus, D. D., & Walkey, A. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.10.049 · Cited by 37
Gillis, A. M., & Skanes, A. C. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.003 · Cited by 35
Zink, M. D., Brüser, C., Winnersbach, P., Napp, A., Leonhardt, S. K., Marx, N., SCHAUERTE, P. N., & Mischke, K. (2015) · BioMed Research International · doi:10.1155/2015/840356 · Cited by 36
Arrhythmogenic Substrates for Atrial Fibrillation in Obesity
Lubbers, E. R., Price, M. V., & Mohler, P. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01482 · Cited by 39
“β-blockers are used in 60–70% of patients with persistent or permanent AF for rate control (Van Gelder et al., 2010; Camm et al., 2011; Dorian and Angaran, 2014).”
BackgroundRole of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling
Guichard, J.-B., Xiong, F., Qi, X., L’Heureux, N., Hiram, R., Xiao, J., Naud, P., Tardif, J., Costa, A. D., & Nattel, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa007 · Cited by 36
Wolfes, J., Ellermann, C., Frommeyer, G., & Eckardt, L. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302056 · Cited by 34
“Nonetheless, interesting differences can often be found in details, which are usually based on a different assessment of the same study, as for example the RACE-II trial [5].”
BackgroundMethodResultAtrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities
Bidaoui, G., Assaf, A. Y. M., & MARROUCHE, N. F. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00691-9 · Cited by 48
“…of Rhythm Management, RACE (Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation), and STAF (Strategies of Treatment of Atrial Fibrillation) trials demonstrated no significant benefit from rhythm control, despite the expected better sinus rhythm management [ 40 –42].”
Atrial Fibrillation in Heart Failure
Lardizabal, J. A., & DEEDWANIA, P. C. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.007 · Cited by 40
“These arbitrary goals are often difficult to accomplish, especially in patients with HF, and have been recently challenged by the results of the Rate Control Efficacy in Permanent Atrial Fibrillation (RACE-II) trial.(36) The study enrolled more than 600 patients with AF, 10% of whom”
ResultKraft, M., Büscher, A., Wiedmann, F., L’hoste, Y., Haefeli, W. E., Frey, N., Katus, H. A., & Schmidt, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638445 · Cited by 33
Atrial Fibrillation and Cancer Patients: Mechanisms and Management
Madnick, D. L., & Fradley, M. G. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01769-3 · Cited by 36
Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation
Chiang, C., Zhang, S., Tse, H., Teo, W. S., Omar, R., & Sriratanasathavorn, C. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.033 · Cited by 34
“However the actual mean achieved heart rate was 93 bpm for patients on lenient rate control group and hence does not prove conclusively that a resting heart rate of >100 bpm is safe [59].”
BackgroundHermans, A. N. L., Isaksen, J. L., Gawalko, M. M., Pluymaekers, N. A. H. A., van der Velden, R. M. J., Snippe, H., Evens, S., Witte, G. D., LUERMANS, J. G. L. M., Manninger, M., et al. (2023) · EP Europace · doi:10.1093/europace/euad011 · Cited by 32
“Statistical analyses The segments were categorized based on the ECG-based 1 min mean heart rate into three rate control ranges: ≤ 80 bpm, 80–110 bpm, and insufficient rate control >110 bpm.(3) We defined an accurate PPG-based assessment of .”
BackgroundMethodWalters, T. E., Wick, K., Tan, G., Mearns, M., Joseph, S., Morton, J. B., Sanders, P., Bryant, C., Kistler, P. M., & Kalman, J. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.101 · Cited by 37
Kato, Y., Suzuki, S. S., Uejima, T., Semba, H., Nagayama, O., Hayama, E., & Yamashita, T. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316633885 · Cited by 31
“between achieved resting HR and cardiovascular morbidity/mortality.(23) Regarding chronic heart failure, many previous studies have observed a close relationship between resting HR and prognosis in SR patients, but not in AF patients.”
ResultDiagnosis and management of canine atrial fibrillation
Pedro, B., Fontes-Sousa, A. P., & Gelzer, A. R. (2020) · The Veterinary Journal · doi:10.1016/j.tvjl.2020.105549 · Cited by 34
(2023) · Australian Prescriber · doi:10.18773/austprescr · Cited by 30
Archetype, adaptation and the mammalian heart
MEIJLER, F. L., & Meijler, T. D. (2011) · Netherlands Heart Journal · doi:10.1007/s12471-011-0086-4 · Cited by 34
Meyer, M., Rambod, M., & LeWinter, M. M. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9660-1 · Cited by 32
Scarsoglio, S., Gallo, C., Saglietto, A., Ridolfi, L., & Anselmino, M. (2019) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2019.04.009 · Cited by 29
Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
Meyer, M., & Lustgarten, D. L. (2023) · EP Europace · doi:10.1093/europace/euad010 · Cited by 31
“m.(3) Although several observational and secondary analyses suggested that beta-blockers were associated with a survival benefit when compared with digoxin, recent results from small randomized studies that directly compared beta-blockers to digoxin or non-dihydropyridine calcium-channel blockers revealed unfavourable…”
BackgroundResultRisk Factors for Bradycardia Requiring Pacemaker Implantation in Patients With Atrial Fibrillation
Barrett, T. W., Abraham, R. L., Jenkins, C. A., Russ, S. E., Storrow, A. B., & Darbar, D. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.06.037 · Cited by 31
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchis, J., & Heras, M. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.04.004 · Cited by 28
Banerjee, A., Marín, F. R., & Lip, G. Y. H. (2011) · Stroke · doi:10.1161/strokeaha.111.617886 · Cited by 35
Hess, P. L., Sheng, S., Matsouaka, R., DeVore, A. D., Heidenreich, P. A., Yancy, C. W., Bhatt, D. L., Allen, L. A., Peterson, P. N., Ho, P. M., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.12.025 · Cited by 32
Wasmer, K., BREITHARDT, G. E., & Eckardt, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu113 · Cited by 31
Hines, M. C., Reed, B. N., Ivaturi, V. D., Bontempo, L. J., Bond, M. C., & Hayes, B. D. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160126 · Cited by 32
Wolfes, J., Ellermann, C., Frommeyer, G., & Eckardt, L. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.12.018 · Cited by 34
Mentz, R. J., Chung, M. J., Gheorghiade, M., Pang, P. S., Kwasny, M., Ambrosy, A. P., Vaduganathan, M., O’Connor, C. M., Swedberg, K. B., Zannad, F. M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.09.011 · Cited by 28
“%) after adjusting for baseline characteristics and known risk factors for AF.30 Previous work also suggests that African Americans may be less likely than whites to be aware of having AF or to be treated with warfarin.31 Thus, the racial differences in AF prevalence, symptoms and treatment highlight the importance of…”
Multimorbidity in Older Adults with Atrial Fibrillation
Chen, M. A. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.01.001 · Cited by 32
“Rate control targets have been studied, most recently in the RACE-II (Rate Control Efficacy in Permanent Atrial Fibrillation) trial, in which a lenient rate control strategy to maintain resting heart rate less than 110 bpm was compared with a strict rate control strategy aimed at a resting rate less than 80 bpm.(7) Th…”
MethodKlein, F. J., Bell, S., Runte, K. E., Lobel, R. M., Ashikaga, T., Lerman, L. O., LeWinter, M. M., & Meyer, M. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00301.2016 · Cited by 28
“An important trial in this regard is the guideline-influencing Rate Efficacy in Permanent Atrial Fibrillation (RACE-2) study (26).”
BackgroundGu, K., Mahtta, D., Kaneria, A., Sharedalal, P., Dennis, B. B., Song, Y., Wei, X., Khalid, U., Hess, P. L., Cho, S.-H., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.064 · Cited by 27
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castellà, M., Dan, G., Dilaveris, P., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.10.022 · Cited by 60
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial
Patel, S. M., Palazzolo, M. G., Murphy, S. A., Antman, E. M., D, E. B. M., Lanz, H., Lip, G. Y. H., Giugliano, R. P., & Ruff, C. T. (2022) · EP Europace · doi:10.1093/europace/euac082 · Cited by 27
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies
Keefe, J. A., Garber, R., McCauley, M. D., & Wehrens, X. H. T. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.016 · Cited by 33
Atrial fibrillation: better symptom control with rate and rhythm management
Gupta, D., Rienstra, M., Gelder, I. C. V., & Fauchier, L. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100801 · Cited by 47
Anguita, M. P., Worner, F., Domenech, P., Marín, F. R., Ortigosa, J., Pérez‐Villacastín, J., Fernández‐Ortíz, A., Alonso, Á., Cequier, A. R., Colet, J. C., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.10.003 · Cited by 26
“Whereas the European guidelines include patients with ventricular hypertrophy secondary to hypertension in this group, Canadian guidelines include any antiarrhythmia when hypertrophy is present, in the absence of other heart diseases and significant repolarization anomalies in the electrocardiogram (which could be a m…”
BackgroundSALTZMAN, H. E. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.005 · Cited by 29
“These targets have been recently challenged by the results of the Rate Control Efficacy in Permanent Atrial Fibrillation (RACE-II) trial.(46) The study enrolled more than 600 patients with AF, who were randomized to either lenient (target resting heart rate <110 beats/min) or strict rate control (target heart rate <80…”
Arrhythmias in Dilated Cardiomyopathy
Kumar, S., Stevenson, W. G., & John, R. M. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.03.005 · Cited by 33
Anselmino, M., Scarsoglio, S., Camporeale, C., Saglietto, A., Gaïta, F., & Ridolfi, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119868 · Cited by 23
Wasmer, K., & Eckardt, L. (2011) · EP Europace · doi:10.1093/europace/eur172 · Cited by 25
Comparing the 2010 North American and European Atrial Fibrillation Guidelines
Gillis, A. M., & Skanes, A. C. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.009 · Cited by 25
“Two further recommendations are made by the CCS panel with respect to anti-coagulation after surgical ablation of AF.19 A large body of evidence monitoring patients after curative procedures for AF, mostly after catheter ablation, highlights the fact that recurrent asymptomatic AF can occur commonly, depending on the…”
MethodInfluentialCeri̇t, L., Duygu, H., Gülşen, K., Kemal, H. S., Özcem, B., Balcıoğlu, Ö., Günsel, A., Tosun, Ö., & Emren, S. V. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.6.798 · Cited by 25
Trohman, R. G., Huang, H. D., & Sharma, P. S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1060030 · Cited by 29
Improved Rate Control Reduces Cardiac Troponin T Levels in Permanent Atrial Fibrillation
Ulimoen, S. R., Enger, S., Norseth, J., Pripp, A. H., Abdelnoor, M., Arnesen, H., Gjesdal, K., & Tveit, A. (2014) · Clinical Cardiology · doi:10.1002/clc.22281 · Cited by 31
Lifestyle risk reduction interventions in atrial fibrillation: a systematic review
Lowres, N., Neubeck, L., Freedman, B., Briffa, T. G., Bauman, A. E., & Redfern, J. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711422505 · Cited by 26
“Data from the REALISE-AF study show that 41% of patients with AF do not have sufficient control of heart rate (HR) or rhythm,(16) although control of either rate or rhythm does not seem to improve prognosis.(17) Disturbingly, patients living with AF experience a range of physical and psychological symptoms, including…”
MethodAtzema, C. L., & Barrett, T. W. (2015) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2014.12.010 · Cited by 25
Pedro, B., Mavropoulou, A., Oyama, M. A., Linney, C., Neves, J., Dukes‐McEwan, J., Fontes-Sousa, A. P., & Gelzer, A. R. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16666 · Cited by 25
Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not?
van Veldhuisen, D. J., Gelder, I. C. V., Ahmed, A., & Gheorghiade, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs483 · Cited by 26
“).(16) Furthermore, and somewhat in line with this, is a recent meta-analysis of four large placebocontrolled, randomized HF trials of the effect of beta-blockers in 1677 patients with AF (and HF)(17) which showed that although beta-blockers significantly reduced heart rate, they did not affect outcome.”
ResultAtrial fibrillation in heart failure: The sword of damocles revisited
Khan, M. A., Ahmed, F. Z., Neyses, L., & Mamas, M. A. (2013) · World Journal of Cardiology · doi:10.4330/wjc.v5.i7.215 · Cited by 22
Emergency medicine considerations in atrial fibrillation
Long, B., Robertson, J., Koyfman, A., Maliel, K., & Warix, J. R. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.01.066 · Cited by 25
Jansson, V., Bergfeldt, L., Schwieler, J. H., Kennebäck, G., Rubulis, A., Jensen, S. M., Raatikainen, P. M. J., Sciaraffia, E., & Blomström‐Lundqvist, C. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100791 · Cited by 25
Perioperative Cardiac Risk Reduction in Noncardiac Surgery
Ganesh, R., Kebede, E., Mueller, M. R., Gilman, E., & Mauck, K. F. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.014 · Cited by 28
Crijns, H. J. G. M., Bash, L. D., Chazelle, F., Heuzey, J. L., Lewalter, T., Lip, G. Y. H., Maggioni, A. P., Martín, A., Ponikowski, P. P., Rosenqvist, M., et al. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-85 · Cited by 22
Self-citationHarskamp, R. E., Fanaroff, A. C., Lópes, R. D., WOJDYLA, D. M., Goodman, S. G., Thomas, L. E., ARONSON, R. S., Windecker, S., Mehran, R., Granger, C. B., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.035 · Cited by 24
Rate or Rhythm Control for Atrial Fibrillation: Update and Controversies
Chinitz, J. S., Halperin, J. L., Reddy, V. Y., & Fuster, V. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.007 · Cited by 27
Medical treatment of atrial fibrillation
Camm, A. J., Camm, C. F., & Savelieva, I. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834f23e1 · Cited by 23
Electrophysiology and heart rhythm disorders in older adults.
Goyal, P., & Rich, M. W. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.08.001 · Cited by 27
Ventricular rate in atrial fibrillation and the risk of heart failure and death
Westergaard, L. M., Alhakak, A., Rørth, R., Fosbøl, E. L., Kristensen, S. L., Svendsen, J. H., Graff, C., Nielsen, J. B., Gislason, G., Køber, L., et al. (2023) · EP Europace · doi:10.1093/europace/euad088 · Cited by 22
“While the AFFIRM trial suggested a mortality benefit in management of AF with rate control over rhythm control, the RACE II trial found that lenient rate-control strategy (resting heart rate <110 bpm) was non-inferior to a strict rate-control strategy (resting heart rate <80 bpm and heart rate during moderate exercise…”
MethodResultAtrial fibrillation: the rate versus rhythm management controversy
Aj, C., & Savelieva, I. (2012) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2012.s03 · Cited by 22
Yamashita, T., & Inoue, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.02.010 · Cited by 22
Oczkowski, S. J. W. (2014) · PubMed Central · Cited by 23
Anselmino, M., Scarsoglio, S., Saglietto, A., Gaïta, F., & Ridolfi, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169967 · Cited by 22
Rate Control in Atrial Fibrillation
Dorian, P. (2010) · New England Journal of Medicine · doi:10.1056/nejme1002301 · Cited by 22
Iwahashi, N., Takahashi, H., Abe, T., Okada, K., Akiyama, E., Matsuzawa, Y., Konishi, M., Maejima, N., Hibi, K., Kosuge, M., et al. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0076 · Cited by 23
Manolis, A. S., Manolis, T. A., Manolis, A. S., & Melita, H. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10221-1 · Cited by 26
“Although there are studies indicating that lenient VR control (resting heart rate target < 110 bpm) is an acceptable strategy in AF patients with HF having similar results with a strict VR control strategy (resting heart rate target < 80 bpm and a heart rate target during moderate exercise < 110 bpm) [39, 40], post ho…”
BackgroundResultPark, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0016 · Cited by 22
Zhang, Z., Zheng, Y., He, W., Wei, J., Li, P., Zhong, G., & Jiang, Z. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14814 · Cited by 20
Drug therapy for heart failure in older patients-what do they want?
Zachariah, D., Taylor, J., Rowell, N., Spooner, C., & Kalra, P. R. (2015) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2015.02.011 · Cited by 20
Atrial Fibrillation in Congenital Heart Disease
de Miguel, I. M., & Ávila, P. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.41 · Cited by 24
Bedford, J., Johnson, A. E. W., Redfern, O., Gerry, S., Doidge, J., Harrison, D. A., Rajappan, K., Rowan, K., Young, D., Mouncey, P., et al. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.11.005 · Cited by 24
de Isla, L. P., Bayés‐Genís, A., Sanchís, J. M., & Heras, M. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70162-7 · Cited by 20
Bontempo, L. J., & Goralnick, E. (2011) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2011.08.008 · Cited by 20
Actualización en cardiología geriátrica
Díaz-Castro, Ó., Datino, T., López‐Palop, R., & Martínez‐Sellés, M. (2011) · Revista Española de Cardiología · doi:10.1016/s0300-8932(11)70002-1 · Cited by 22
Can We Predict Outcomes in Atrial Fibrillation?
Desai, N. R., & Giugliano, R. P. (2012) · Clinical Cardiology · doi:10.1002/clc.20989 · Cited by 21
Update on the management of atrial fibrillation
Amerena, J. V., Walters, T. E., Mirzaee, S., & Kalman, J. M. (2013) · The Medical Journal of Australia · doi:10.5694/mja13.10191 · Cited by 21
EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION
Sp, G., Панченко, Е. П., Станиславовна, К. Е., Laiovich, L. I., Maykov, E. B., Mironov, N. Y., & Shakhmatova, O. O. (2019) · Eurasian heart journal · doi:10.38109/2225-1685-2019-4-4-85 · Cited by 23
Prognostic Significance of Atrial Arrhythmias in a Primary Prevention ICD Population
Gelder, I. C. V., Phan, H., Wilkoff, B. L., BROWN, M. L., Rogers, T. B., PETERSON, B. J., & Birgersdotter-Green, U. M. (2011) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2011.03124.x · Cited by 20
Clinical U pdate on the M anagement of A trial F ibrillation
Danelich, I. M., Reed, B. N., Hollis, I. B., Cook, A. M., & Rodgers, J. E. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1217 · Cited by 21
“In the meantime, rate control is currently recommended as the therapy of choice in the majority of patients with AF.2, 5 It is especially preferred in patients older than 65 years and in those with significant comorbid cardiovascular disease.”
MethodInfluentialCoronary artery diseases in Japanese patients with nonvalvular atrial fibrillation
Senoo, K., Suzuki, S. S., Sagara, K., Otsuka, T., Matsuno, S., Uejima, T., Oikawa, Y., Yajima, J., Nagashima, K., Kirigaya, H., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.08.007 · Cited by 20
Atrial fibrillation in chronic kidney disease
Voroneanu, L. E., Ortíz, A., Nistor, I., & Covic, A. C. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.04.007 · Cited by 22
Mulder, B. A., Damman, K., van Veldhuisen, D. J., Gelder, I. C. V., & Rienstra, M. (2017) · Clinical Cardiology · doi:10.1002/clc.22725 · Cited by 26
“After a median of 3 years of follow-up, no differences were observed between lenient (below 110 bpm) and strict (below 80 bpm) rate control in terms of cardiovascular morbidity and mortality.(13) Despite the absence of a difference in HF hospitalization in RACE II, one cannot exclude that excessive heart rates (eg, he…”
BackgroundInfluentialBarnett, A. S., Lewis, W. R., Field, M. E., Fonarow, G. C., Gersh, B. J., Page, R. L., Calkins, H. G., Steinberg, B. A., Peterson, E. D., & Piccini, J. P. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4936 · Cited by 20
Classification and choice of antiarrhythmic therapies
Barton, A. K., McGowan, M., Smyth, A., Wright, G. A., & Gardner, R. S. (2020) · Prescriber · doi:10.1002/psb.1828 · Cited by 22
Pérez, A., Touchette, D. R., DiDomenico, R. J., Stamos, T. D., & Walton, S. M. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.552 · Cited by 20
“28 Also, current atrial fibrillation guidelines recommend aggressive rate control, but recommendations might change based on recent findings in which lenient rate control is as effective as strict rate control.(36) The recently published European Society of Cardiology guidelines continue to recommend that the choice t…”
BackgroundManagement of Atrial Fibrillation
Moukabary, T., & Gonzalez, M. D. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.007 · Cited by 19
Atrial fibrillation: an epidemic in the elderly
Riley, A. B., & Manning, W. J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.107 · Cited by 21
Tachycardiomyopathy in Patients without Underlying Structural Heart Disease
Stronati, G., Guerra, F., Urbinati, A., Ciliberti, G., Cipolletta, L., & Capucci, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091411 · Cited by 22
“This is in contrast to the known evidence that both the heart rate targets are considered similarly effective in preventing adverse events in patients with AF [19].”
ResultRotors as Drivers of Atrial Fibrillation and Targets for Ablation
Schricker, A. A., Lalani, G., Krummen, D. E., & Narayan, S. M. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0509-0 · Cited by 27
Rodríguez‐Mañero, M., Otero-Raviña, F., García‐Seara, J., Zugaza-Gurruchaga, L., Rodríguez-García, J. M., Blanco-Rodríguez, R., Turrado, V. T., Fernández-Villaverde, J. M., Vidal-Pérez, R., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.01.015 · Cited by 18
Fibrilación auricular en cirugía cardíaca
Baeza-Herrera, L. A., Rojas‐Velasco, G., Márquez-Murillo, M. F., Portillo-Romero, A. D. R., Medina-Paz, L., Álvarez‐Álvarez, R. J., Ramos‐Enríquez, Á., & Baranda-Tovar, F. M. (2019) · Archivos de cardiología de México · doi:10.24875/acm.19000134 · Cited by 20
Metadata
- Authors
- Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., Tukkie, R., Bosker, H. A., Van Veldhuisen, D. J., & Van den Berg, M. P.
- Affiliations
- University Medical Center Groningen (NL)
- Maastricht University Medical Centre (NL)
- Deventer Ziekenhuis (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Medisch Centrum Alkmaar (NL)
- Rijnstate Hospital (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-15
- Volume
- 362
- Issue
- 15
- Pages
- 1363-1373
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102129403
- Cited by
- 1,033
- References
- 19
- Citations by year
- 2026: 36 · 2025: 55 · 2024: 59 · 2023: 61 · 2022: 56 · 2021: 63 · 2020: 44 · 2019: 50 · 2018: 45 · 2017: 62 · 2016: 56 · 2015: 51 · 2014: 81 · 2013: 94 · 2012: 83
- FWCI
- 68.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Keywords
- atrial fibrillation, rate control, resting heart rate, non-inferiority, cardiovascular morbidity and mortality, heart failure hospitalization, stroke, hemorrhage, arrhythmic events, anticoagulation
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Calcium Channel Blockers, Female, Follow-Up Studies, Heart Rate, Humans, Male, Middle Aged, Confidence Intervals, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.